

Date: October 29, 2026

To,
Sr. General Manager
Listing Department
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai – 400 001

BSE Scrip Code: 544319

To,
Sr. General Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G
Bandra Kurla Complex
Bandra (E), Mumbai – 400 051

NSE Symbol: SENORES

Sub.: Disclosure under Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir/Ma'am,

We are pleased to inform you that the Board of Directors of the Company at their meeting held today, i.e., Thursday, October 29, 2026, has noted that the Company's various subsidiary companies have planned capacity expansion in their existing manufacturing facilities. The details of the indicative capacity expansions are as below:

Name of the Subsidiary	Existing Capacity (per annum)	Enhanced Capacity (per annum)	Estimated Cost (INR in Cr)
Havix Group INC, USA	1.2 Bn units	2.0 Bn units	18.00
Apnar Pharma Private Limited, India	0.5 Bn units	1.2 Bn units	20.00

In addition to the above the Board has also noted that the subsidiary company Ratnatris Pharmaceuticals Private Limited is in process of adding a new Prefilled Syringe (PFS) line with a capacity of 2.7 Mn units (per annum) at an estimated cost of INR 5.00 Crores.

All the proposed expansions are likely to be completed by end of March 2027.

As a part of Good Corporate Governance and with a view of maintaining transparency and keeping investors and other stakeholders informed, the Company wishes to place the above information on record.

The details as required pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations, 2015 read with the SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, is given in the Annexure- A.

Senores Pharmaceuticals Limited

1101 to 1103, 11th Floor, South Tower, One42, Opp. Jayantilal Park,
Ambali Bopal Road, Ahmedabad-380054, Gujarat, India

P: +91 79 2999 9857 | E: info@senorespharma.com

W: www.senorespharma.com | CIN No.: L24290GJ2017PLC100263

You are requested to take the same on record.

Thanking you.

For Senores Pharmaceuticals Limited

**SHILPA
SHARMA**

Digitally signed by SHILPA
SHARMA
DN: cn=SHILPA SHARMA, c=IN,
o=Personal,
email=csshilpa.agarwal@gmail.com
Date: 2026.10.29 13:56:55 +05'30'

Shilpa Sharma

Company Secretary & Compliance Officer

Membership Number: A34516

Annexure-A

Sr. No	Particulars	Havix Group INC, USA (subsidiary)	Apnar Pharma Private Limited
1.	Existing capacity	1.2 Bn units	0.5 Bn units
2.	Existing Capacity utilisation	Approximately 50-70%	
3.	Proposed capacity addition	0.8 Bn units	0.7 Bn units
4.	Period within which the proposed capacity is to be added	The proposed capacity addition to be completed by end of March 2027	
5.	Investment required	INR 18.00 crores	INR 20.00 crores
6.	Mode of financing	Internal accruals and IPO proceeds	
7.	Rationale of such increase	To meet the existing and future demand	

Senores Pharmaceuticals Limited

1101 to 1103, 11th Floor, South Tower, One42, Opp. Jayantilal Park,
Ambali Bopal Road, Ahmedabad-380054, Gujarat, India

P: +91 79 2999 9857 | E: info@senorespharma.com

W: www.senorespharma.com | CIN No.: L24290GJ2017PLC100263